{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:45:11Z","timestamp":1785527111938,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07911-5","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:29:34Z","timestamp":1779319774000},"page":"5627-5643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical Alzheimer's disease spectrum classified in the A\/T\/N framework with 18F-Flutemetamol-Centiloid, 18F-MK-6240-CenTauR, and 18F-FDG-AD metaROI: a multicenter memory clinic observational study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6596-5662","authenticated-orcid":false,"given":"Vere Rose","family":"Megens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-4620","authenticated-orcid":false,"given":"Peter Wessel","family":"Strandhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-3739","authenticated-orcid":false,"given":"Erik Magnus","family":"Berntsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3964-6055","authenticated-orcid":false,"given":"Ebba Gl\u00f8ersen","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-7245","authenticated-orcid":false,"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3411-8317","authenticated-orcid":false,"given":"Live","family":"Eikenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-1202","authenticated-orcid":false,"given":"Asta K.","family":"Haberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"180\u02daN Cognitive Impairment Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Aam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannveig Sakshaug","family":"Eldholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid R\u00e5ket","family":"Moholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Christian J\u00f8raholmen","family":"Fl\u00f8vig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene Haugen","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f8ril Rolfseng","family":"Gr\u00f8ntvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild Tina","family":"Saltvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel Karl Gottfrid","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngve M\u00fcller","family":"Seljeseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer Harish Kumar","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild Eide","family":"Skogseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Mykhailova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv Toril","family":"M\u00f8en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nj\u00e5l","family":"Brekke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Haugarvoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Biermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunn Tove","family":"Lium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"7911_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/wnl.0000000000002923","volume":"87","author":"CR Jack Jr.","year":"2016","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347. https:\/\/doi.org\/10.1212\/wnl.0000000000002923.","journal-title":"Neurology"},{"key":"7911_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(20)32205-4.","journal-title":"Lancet"},{"key":"7911_CR3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"7911_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394. https:\/\/doi.org\/10.1001\/jamaneurol.2014.4144.","journal-title":"JAMA Neurol"},{"key":"7911_CR5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599\u2013606. https:\/\/doi.org\/10.2967\/jnumed.115.171678.","journal-title":"J Nucl Med"},{"key":"7911_CR6","doi-asserted-by":"publisher","first-page":"8497","DOI":"10.1038\/s41467-024-52265-x","volume":"15","author":"P Kunach","year":"2024","unstructured":"Kunach P, Vaquer-Alicea J, Smith MS, Monistrol J, Hopewell R, Moquin L, et al. Cryo-EM structure of Alzheimer\u2019s disease tau filaments with PET ligand MK-6240. Nat Commun. 2024;15:8497. https:\/\/doi.org\/10.1038\/s41467-024-52265-x.","journal-title":"Nat Commun"},{"key":"7911_CR7","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1212\/wnl.0000000000201389","volume":"100","author":"S Shimohama","year":"2023","unstructured":"Shimohama S, Tezuka T, Takahata K, Bun S, Tabuchi H, Seki M, et al. Impact of amyloid and tau PET on changes in diagnosis and patient management. Neurology. 2023;100:e264\u201374. https:\/\/doi.org\/10.1212\/wnl.0000000000201389.","journal-title":"Neurology"},{"key":"7911_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-022-05999-z","volume":"50","author":"J Wang","year":"2023","unstructured":"Wang J, Jin C, Zhou J, Zhou R, Tian M, Lee HJ, et al. PET molecular imaging for pathophysiological visualization in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2023;50:765\u201383. https:\/\/doi.org\/10.1007\/s00259-022-05999-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7911_CR9","doi-asserted-by":"publisher","first-page":"e1692","DOI":"10.1212\/WNL.0000000000200148","volume":"98","author":"LE Collij","year":"2022","unstructured":"Collij LE, Salvad\u00f3 G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, et al. Spatial-temporal patterns of \u03b2-amyloid accumulation: A subtype and stage inference model analysis. Neurology. 2022;98:e1692\u2013703. https:\/\/doi.org\/10.1212\/WNL.0000000000200148.","journal-title":"Neurology"},{"key":"7911_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","volume":"20","author":"J Therriault","year":"2024","unstructured":"Therriault J, Schindler SE, Salvad\u00f3 G, Pascoal TA, Benedet AL, Ashton NJ, et al. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nat Rev Neurol. 2024;20:232\u201344. https:\/\/doi.org\/10.1038\/s41582-024-00942-2.","journal-title":"Nat Rev Neurol"},{"issue":"1\u201315","key":"7911_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1\u201315):e1-4. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"key":"7911_CR12","doi-asserted-by":"publisher","first-page":"e12454","DOI":"10.1002\/dad2.12454","volume":"15","author":"VL Villemagne","year":"2023","unstructured":"Villemagne VL, Leuzy A, Bohorquez SS, Bullich S, Shimada H, Rowe CC, et al. CenTauR: Toward a universal scale and masks for standardizing tau imaging studies. Alzheimers Dement (Amst). 2023;15:e12454. https:\/\/doi.org\/10.1002\/dad2.12454.","journal-title":"Alzheimers Dement (Amst)"},{"key":"7911_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/alz.13355","volume":"20","author":"C Boccalini","year":"2024","unstructured":"Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti DE, Mu L, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimers Dement. 2024;20:221\u201333. https:\/\/doi.org\/10.1002\/alz.13355.","journal-title":"Alzheimers Dement"},{"key":"7911_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13:205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2016.08.005.","journal-title":"Alzheimers Dement"},{"key":"7911_CR15","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s00259-024-07063-4","volume":"52","author":"C Boccalini","year":"2025","unstructured":"Boccalini C, Peretti DE, Mathoux G, Iaccarino L, Ribaldi F, Scheffler M, et al. Early-phase (18)F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer\u2019s disease: a comparison with (18)F-FDG-PET and early-phase amyloid-PET. Eur J Nucl Med Mol Imaging. 2025;52:1958\u201369. https:\/\/doi.org\/10.1007\/s00259-024-07063-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7911_CR16","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41593-025-02000-6","volume":"28","author":"R Ossenkoppele","year":"2025","unstructured":"Ossenkoppele R, Coomans EM, Apostolova LG, Baker SL, Barthel H, Beach TG, et al. Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-beta status. APOE genotype and sex Nat Neurosci. 2025;28:1610\u201321. https:\/\/doi.org\/10.1038\/s41593-025-02000-6.","journal-title":"APOE genotype and sex Nat Neurosci"},{"key":"7911_CR17","doi-asserted-by":"publisher","first-page":"251652-","DOI":"10.1002\/alz70862_109695","volume":"66","author":"C Rowe","year":"2025","unstructured":"Rowe C, Dore V, Feizpour A, Bourgeat P, Leuzy A, Mulligan R, et al. CenTauR correlation with amyloid, atrophy and cognition across the Alzheimer\u2019s Disease spectrum: a tau imaging study with 18F-MK6240 PET. J Nucl Med. 2025;66:251652-. https:\/\/doi.org\/10.1002\/alz70862_109695.","journal-title":"J Nucl Med"},{"key":"7911_CR18","doi-asserted-by":"publisher","first-page":"e70520","DOI":"10.1002\/alz.70520","volume":"21","author":"BJ Lopresti","year":"2025","unstructured":"Lopresti BJ, Cohen AD, DelBene A, Reese A, Matan C, Gogola A, et al. Comparison of visual and analytic methods of Alzheimer\u2019s disease pathologic staging. Alzheimers Dement. 2025;21:e70520. https:\/\/doi.org\/10.1002\/alz.70520.","journal-title":"Alzheimers Dement"},{"key":"7911_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13195-025-01839-y","volume":"17","author":"P Coupe","year":"2025","unstructured":"Coupe P, Mansencal B, Morandat F, Morell-Ortega S, Villain N, Manjon JV, et al. petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI. Alzheimers Res Ther. 2025;17:209. https:\/\/doi.org\/10.1186\/s13195-025-01839-y.","journal-title":"Alzheimers Res Ther"},{"key":"7911_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s42003-020-1079-x","volume":"3","author":"TC Hammond","year":"2020","unstructured":"Hammond TC, Xing X, Wang C, Ma D, Nho K, Crane PK, et al. \u03b2-amyloid and tau drive early Alzheimer\u2019s disease decline while glucose hypometabolism drives late decline. Commun Biol. 2020;3:352. https:\/\/doi.org\/10.1038\/s42003-020-1079-x.","journal-title":"Commun Biol"},{"key":"7911_CR21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1212\/wnl.0b013e3181bc010c","volume":"73","author":"WJ Jagust","year":"2009","unstructured":"Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193\u20139. https:\/\/doi.org\/10.1212\/wnl.0b013e3181bc010c.","journal-title":"Neurology"},{"key":"7911_CR22","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.2967\/jnumed.124.268756","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21:e14338. https:\/\/doi.org\/10.2967\/jnumed.124.268756.","journal-title":"Alzheimers Dement"},{"key":"7911_CR23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-021-05603-w","volume":"49","author":"E Guedj","year":"2022","unstructured":"Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, et al. EANM procedure guidelines for brain PET imaging using [(18)F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49:632\u201351. https:\/\/doi.org\/10.1007\/s00259-021-05603-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7911_CR24","unstructured":"EMA. Vizamyl: EPAR - Product Information. European Public Assessment Report (EPAR) for Vizamyl. European Medicines Agency: European Medicines Agency; 2014;38."},{"key":"7911_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13550-019-0553-2","volume":"9","author":"SK Oen","year":"2019","unstructured":"Oen SK, Keil TM, Berntsen EM, Aanerud JF, Schwarzlmuller T, Ladefoged CN, et al. Quantitative and clinical impact of MRI-based attenuation correction methods in [(18)F]FDG evaluation of dementia. EJNMMI Res. 2019;9:83. https:\/\/doi.org\/10.1186\/s13550-019-0553-2.","journal-title":"EJNMMI Res"},{"key":"7911_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand (18)F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. J Nucl Med. 2019;60:93\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.209650.","journal-title":"J Nucl Med"},{"key":"7911_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351\u20136. https:\/\/doi.org\/10.2214\/ajr.149.2.351.","journal-title":"AJR Am J Roentgenol"},{"key":"7911_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/bf00868807","volume":"242","author":"P Scheltens","year":"1995","unstructured":"Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242:557\u201360. https:\/\/doi.org\/10.1007\/bf00868807.","journal-title":"J Neurol"},{"key":"7911_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.21037\/qims-21-188","volume":"12","author":"EG Muller","year":"2022","unstructured":"Muller EG, Stokke C, Stokmo HL, Edwin TH, Knapskog AB, Revheim ME. Evaluation of semi-quantitative measures of (18)F-flutemetamol PET for the clinical diagnosis of Alzheimer\u2019s disease. Quant Imaging Med Surg. 2022;12:493\u2013509. https:\/\/doi.org\/10.21037\/qims-21-188.","journal-title":"Quant Imaging Med Surg"},{"key":"7911_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","volume":"8","author":"MR Battle","year":"2018","unstructured":"Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8:107. https:\/\/doi.org\/10.1186\/s13550-018-0456-7.","journal-title":"EJNMMI Res"},{"key":"7911_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J, et al. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [(18)F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48:302\u201310. https:\/\/doi.org\/10.1007\/s00259-020-04942-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7911_CR32","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1002\/alz.14336","volume":"20","author":"LE Collij","year":"2024","unstructured":"Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Ro\u00e9-Vellv\u00e9 N, et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement. 2024;20:9037\u201348. https:\/\/doi.org\/10.1002\/alz.14336.","journal-title":"Alzheimers Dement"},{"key":"7911_CR33","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/hbm.25774","volume":"43","author":"Y Li","year":"2022","unstructured":"Li Y, Ng YL, Paranjpe MD, Ge Q, Gu F, Li P, et al. Tracer-specific reference tissues selection improves detection of (18) F-FDG, (18) F-florbetapir, and (18) F-flortaucipir PET SUVR changes in Alzheimer\u2019s disease. Hum Brain Mapp. 2022;43:2121\u201333. https:\/\/doi.org\/10.1002\/hbm.25774.","journal-title":"Hum Brain Mapp"},{"key":"7911_CR34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ana.23650","volume":"72","author":"SM Landau","year":"2012","unstructured":"Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578\u201386. https:\/\/doi.org\/10.1002\/ana.23650.","journal-title":"Ann Neurol"},{"key":"7911_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/alz.091613","author":"T Schwartz","year":"2024","unstructured":"Schwartz T, Robb WH, Bishay S, Jackson TB, Jefferson AL, Landman BA, et al. Prevalence of hypometabolism in AD\u2010related regions in real\u2010world FDG\u2010PET of the brain. Alzheimers Dement. 2024. https:\/\/doi.org\/10.1002\/alz.091613.","journal-title":"Alzheimers Dement"},{"key":"7911_CR36","unstructured":"Metodebok.no. Nevromark\u00f8rer: beta-amyloid42 (A\u03b242), fosfotau (P-tau181), totaltau (T-tau), SP. 3.2 ed. metodebok.no: Norsk forening for medisinsk biokjemi."},{"key":"7911_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-019-0917-z","volume":"19","author":"C Pettigrew","year":"2019","unstructured":"Pettigrew C, Soldan A. Defining cognitive reserve and implications for cognitive aging. Curr Neurol Neurosci Rep. 2019;19:1. https:\/\/doi.org\/10.1007\/s11910-019-0917-z.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"7911_CR38","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","volume":"48","author":"V Dor\u00e9","year":"2021","unstructured":"Dor\u00e9 V, Krishnadas N, Bourgeat P, Huang K, Li S, Burnham S, et al. Relationship between amyloid and tau levels and its impact on tau spreading. Eur J Nucl Med Mol Imaging. 2021;48:2225\u201332. https:\/\/doi.org\/10.1007\/s00259-021-05191-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7911_CR39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268119","author":"LE Collij","year":"2024","unstructured":"Collij LE, Bischof GN, Altomare D, Bader I, Battle M, V\u00e1llez Garc\u00eda D, et al. Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.124.268119.","journal-title":"J Nucl Med"},{"key":"7911_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11307-021-01660-7","volume":"24","author":"GS de Souza","year":"2022","unstructured":"de Souza GS, Andrade MA, Borelli WV, Schilling LP, Matushita CS, Portuguez MW, et al. Amyloid-\u03b2 PET classification on cognitive aging stages using the Centiloid scale. Mol Imaging Biol. 2022;24:394\u2013403. https:\/\/doi.org\/10.1007\/s11307-021-01660-7.","journal-title":"Mol Imaging Biol"},{"key":"7911_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-020-00765-5","volume":"13","author":"JS Sanchez","year":"2021","unstructured":"Sanchez JS, Hanseeuw BJ, Lopera F, Sperling RA, Baena A, Bocanegra Y, et al. Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer\u2019s disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimers Res Ther. 2021;13:27. https:\/\/doi.org\/10.1186\/s13195-020-00765-5.","journal-title":"Alzheimers Res Ther"},{"key":"7911_CR42","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3233\/jad-215292","volume":"85","author":"H Ahn","year":"2022","unstructured":"Ahn H, Yi D, Chu K, Joung H, Lee Y, Jung G, et al. Functional neural correlates of semantic fluency task performance in mild cognitive impairment and Alzheimer\u2019s disease: an FDG-PET study. J Alzheimers Dis. 2022;85:1689\u2013700. https:\/\/doi.org\/10.3233\/jad-215292.","journal-title":"J Alzheimers Dis"},{"key":"7911_CR43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000161055","volume":"26","author":"DY Lee","year":"2008","unstructured":"Lee DY, Seo EH, Choo IH, Kim SG, Lee JS, Lee DS, et al. Neural correlates of the clock drawing test performance in Alzheimer\u2019s disease: a FDG-PET study. Dement Geriatr Cogn Disord. 2008;26:306\u201313. https:\/\/doi.org\/10.1159\/000161055.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"7911_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/arclin\/9.5.395","volume":"9","author":"KA Welsh","year":"1994","unstructured":"Welsh KA, Hoffman JM, Earl NL, Hanson MW. Neural correlates of dementia: regional brain metabolism (FDG-PET) and the CERAD neuropsychological battery. Arch Clin Neuropsychol. 1994;9:395\u2013409.","journal-title":"Arch Clin Neuropsychol"},{"key":"7911_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3233\/jad-170578","volume":"67","author":"GA Marshall","year":"2019","unstructured":"Marshall GA, Gatchel JR, Donovan NJ, Muniz MC, Schultz AP, Becker JA, et al. Regional tau correlates of instrumental activities of daily living and apathy in mild cognitive impairment and Alzheimer\u2019s disease dementia. J Alzheimers Dis. 2019;67:757\u201368. https:\/\/doi.org\/10.3233\/jad-170578.","journal-title":"J Alzheimers Dis"},{"key":"7911_CR46","doi-asserted-by":"publisher","first-page":"e12118","DOI":"10.1002\/dad2.12118","volume":"12","author":"GA Marshall","year":"2020","unstructured":"Marshall GA, Sikkes SAM, Amariglio RE, Gatchel JR, Rentz DM, Johnson KA, et al. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020;12:e12118. https:\/\/doi.org\/10.1002\/dad2.12118.","journal-title":"Alzheimers Dement (Amst)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07911-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07911-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07911-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:55Z","timestamp":1785521335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07911-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7911"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07911-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this study was obtained from the Regional Committees for Medical and Health Research Ethics for the region of mid-Norway (REK number 536745).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent before any study-related procedures were conducted.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SA has been a consultant in Eisai\u2019s National Norwegian Alzheimer\u2019s disease Advisory Board meetings.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}